Member Info for ahha

Can anyone explain why HUNTSWORTH shares are no longer listed in the Financial Times?

500,000 AND 1,500000 shares changing hands.......what is going on? Something is going on! Any ideas anyone? And why has Huntsworth disappeared from the FT?

According to this site the p/e is 12.8 according to Sally Withey it is just 7 who is right? If it is the later....then maybe this share could resonably be worth at least 70 -85p Who works out the P/E on this site? Anyway, today's advance is most encouraging....quite an increase in shareholder activity........together with a general upturn in interest in the PR sector generally.....hmmmmm

WHY does the information on THIS discussion board say that it is 11.951 ? How can we make informed decisions about shares on inaccurate information? WHO is right.....Sally Withey or this discussion board? If Sally has not been misquoted, then I would submit, my learned friends, that HUNTSWORTH shares are far too cheap! Where is my 'learned friend' ......"Mulled Wine"........ he curiously has made no comment about the latest encouraging results of Huntsworth.

So reports the excellent Jessica Furseth of the Investor's Chronicle: "Chief operating officer Sally Withey of media agency Huntsworth is optimistic about the company's "robust pipeline" of business. In the first half, adjusted pre-tax profits rose 21 per cent to £11.6m, despite revenues holding flat, and with the benefits of multi-office contracts now trickling through to the bottom line, Huntsworth remains an attractive recovery play on a lowly PE ratio of 7 and offering a chunky 7 per cent yield."

Fear not! Lord Chadlington will not cease from mental fight, nor will his sword sleep in his hand, till he has built Jerusalem in England's green and pleasant land! In short, the company is in highly capable hands and only a little unexpected good news will restore the fortunes of this share....AND you will get 7% yeild and a juicy dividend while you wait.

Peter Chadlington, Chief Executive of Huntsworth, said: "We have seen a 21% increase in profits before tax compared to the first half of last year. This is a result of our rigorous cost control combined with the changing profile of the Group's revenue stream gathering pace with global and multi-office revenues growing strongly in the period and now accounting for almost half of Group revenues.

Something very odd has happened! For at least 4 weeks now HUNSWORTH SHARES have stopped appearing in the Financial Times....can anyone explain why? Why doesn't Huntsworth want to attract attention to its self? It is usualy under the 'Media ' section....but I could not find it.........and was not under support services either. Hmmmmmmmm?

I have faithfully followed this share for well over 10 years...........back then the shares reached £4.00 just on the hint that Varisolve would be a block buster remedy for varicose viens........but it was very premature as there were so many saftey trials to pass through before it could be brought to market. Since then BTG has transformed itself, it has tons of cash....and MANY more money making drugs....and varisolve is just about to hit the big time in the USA! This share is a firm buy and possibly even a takeover target.....so fill your boots!

I thought this site was here to help people make informed decisions about shares under discussion. So why has it removed all past share news? I seem to remember one of the top brokers predicting that this share was destined to reach a target of £4.30p This was when the price was around £3.80.......it looks as this price will soon be realised!

It is all very strange.......a Director bought 10,000 shares recently..........the first buy after a long time.......all records have been removed.........I find this very strange. perhaps Mulled Wine can throw some light on the matter.

VERY NICE NOTE FROM DANIEL STEWART BACKING UP THE PROFITABLE GROWTH NOW AND INTO THE FUTURE BTG again exceeded our expectations: FY12 PBT-DSC was £39.3m vs. £33.8m expected. Moreover, the group’s flagship product, Varisolve, is firmly on track for a US launch in 2014. Investment Case ␣ Flagship product, Varisolve, on track for US launch in 2014. ␣ Licensing & Biotech division seeing strong growth in royalty income from Zytiga. Lemtrada and CytoFab in the pipeline. ␣ Smooth transfer to direct sales into the US market by Specialty Pharma Division. Upside from 417p to 429p Buy 11% What’s Changed (since 16/04/2012) Company Description International specialty pharmaceuticals company www.btgplc.com Results exceeded expectations BTG consistently exceeds expectations. As a result, the group’s share price continues to outperform the market. Results BTG’s final results for the year ended 31 March 2012 exceeded our expectations. Exceeding expectations Revenue increased by 77% to £197.0m (FY03/11: £111.4m), vs. £191.6m expected. Reported Profit before tax was £23.0m (FY03/11: loss of £10.8m), vs. £18.8m expected. PBT-DSC was £39.3m (FY03/11: £5.1m), vs. £33.8m expected. EPS-DSC were 11.9p (FY03/11: 1.9p), vs. 10.2p expected. Cash and equivalents, together with cash on fixed term deposits was £111.9m at 31 March 2012 (£73.9m at 31 March 2011), vs. £99.4m expected. Of note, the group generated £40.1m of Free Cash Flow over the period, vs. a £32.4m loss in FY03/11. We estimate that BTG will remain cash generative going forward. Forecasts As a result of BTG’s performance, we increased our FY03/13 forecasts to: Sales of £189.2m (previously £181.7m), PBT-DSC of £30.1m (£22.1m) and EPS-DSC of 9.1p (6.7p). We also issued FY03/14 forecasts: Sales of £201.0m, PBT-DSC of £38.2m, and EPS-DSC of 11.6p. Outperformance continues Since we initiated coverage of BTG in June 2010, the share price has increased by over 100%. Over the same period, benchmark indexes remained relatively flat (Chart 1). We believe that this impressive track record of outperformance clearly demonstrates management’s ability to create shareholder value. On the strength of BTG's product pipeline, and given management's current business strategy, we are confident that the company’s share price will continue to outperform the market well into the future.

Why have all the tremendously positive posts concerning this company disappeared? BTG will continue to deliver excellent results with an enormous ammount of good news in the pipe line! It has a block busting drug for prostate cancer and "varisolve" a very cost effective remedy for varicose veins that could make a fortune in the USA. The company could also eyed by other companies as a possible takeover target. I have 100% faith in this company having held the shares for 10 years. Highly significant is that when all other shares are falling this one keeps rising....and even during the worst of the market jitters......the share price has held firm. BUY! BUY! BUY!

First Director buy of 10,000 shares at £3.60 fot well over a year! Maybe he has been reading this site! Anyway, it further confirms that this share is worth buying.

40,000 sold and 315,000 bought again today! It's looking good!

I am most gratified to see that Finncap has at long last capitulated...... and decided to agree with me about the prospects of BTG! Of course anything can happen in the following weeks to the price with the dreadful Euro situation, but my rock solid advice is to buy strongly on any weakness cos this share is as close to a winner as any share I have seen in quite a while!!!

Another 255,000 buy at close of business on the 18th May..........over half a million traded. Over 400,000 bought today alone....... when everyone else is selling. It's looking good!

360,000 shares bought on 15th May and 160,000 bought today, 18th May. With an 8.33% yeild and broker recommendations of hold and possible 57p target price.......shares look good value.

"As the uncertain economic outlook - particularly in Europe - continues, management is keeping tight control of costs and therefore, even with modest full year revenue growth, expects improvement in operating margins and profitability for the first half and for the year as a whole.

I remain a firm supporter of this company and believe it will produce great returns for the patient. However, I wonder why there is so little director buying? Is it because they feel the market will drag the current price down? Or is it that they have little faith in their company? It seems to me that there is enormous potential for big prifts in the pipeline.......so why no director buys? hmmmm